CRONCronos Group Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~6% a year FCF growth. The price demands less than its three-year revenue growth of 30% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CRON's price assumes
Cronos Group Inc. trades at 16.1× earnings against 19.7× for the median Drug Manufacturers - Specialty & Generic name, cheaper than its own group.
Trailing P/E · Drug Manufacturers - Specialty & Generic median 19.7 · cheaper than the typical name in its group
- Price / sales
- 5.72
Price / sales · as of 2026-Q2
- Free cash flow yield
- 4.9%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +6.0%
Growth the price implies · The price pays for +6.0% free cash flow growth a year for a decade; revenue has grown +30% a year over the last three.
Details›
- Price / bookas of 2026-Q2
- 0.96
- EV / EBIToperating margin −1.4%: the multiple describes the denominator
- not meaningful
- Healthcare median P/E509 names
- 26.2
- Drug Manufacturers - Specialty & Generic median P/E45 names
- 19.7
- Free cash flow, trailing twelve months
- $50M
- Market capitalisation
- $1.02B
- 3-year revenue growth
- +30%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
Ranks #33 of 41 by RyuScore